drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (ADC)
drug_description
An antibody–drug conjugate targeting Nectin-4 (PVRL4). The monoclonal antibody binds Nectin-4 on tumor cells, is internalized, and releases an intracellular cytotoxic payload to kill the cancer cell; Fc-mediated effector functions may also contribute. Evaluated in advanced solid tumors including urothelial cancer, triple-negative breast cancer, and cervical cancer.
nci_thesaurus_concept_id
C201920
nci_thesaurus_preferred_term
Anti-nectin-4 Antibody-drug Conjugate ADRX-0706
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4) that is conjugated to the tubulin inhibitor and cytotoxic agent AP052, with potential antineoplastic activity. Upon administration of the anti-nectin-4 ADC ADRX-0706, the anti-nectin-4 antibody targets and binds to nectin-4 expressed on tumor cells. Upon binding and internalization, AP052 targets and binds to tubulin, and inhibits its polymerization. This results in G2/M phase arrest and induces apoptosis in nectin-4-expressing tumor cells. Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue. It is associated with poor disease prognosis. ADRX-0706 has a drug-antibody ratio (DAR) of eight.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Monoclonal antibody targets Nectin-4 (PVRL4) on tumor cells, is internalized, and releases a tubulin-inhibiting cytotoxic payload (AP052), leading to inhibition of microtubule polymerization, G2/M arrest, and apoptosis in Nectin-4–expressing cells; Fc-mediated effector functions may also contribute.
drug_name
ADRX-0706
nct_id_drug_ref
NCT06036121